Moderna Skids As $19 Billion Covid Vaccine Sales Outlook Lags Expectations

Moderna stock toppled on Thursday after the Covid vaccine-maker reported adjusted income of $11.29 per share on $7.21 billion in fourth-quarter sales.

On average, analysts polled by FactSet expected Moderna (MRNA) to earn $9.96 per share on $6.8 billion in sales. The company's Covid vaccine generated $6.9 billion in sales, based on 297 million doses.